Daily Dose of Meclofenoxate: 250-750mg
Maclofenoxate, or Centrophenoxine, is a nootropic supplement, which means it can be used as a brain enhancer. This smart drug is a compound of both dimethylaminoethanol (DMAE) and parachlorophenoxyacetate (pCPA). It is commonly used to treat and manage Alxheimer’s disease and senile dementia, though it is used by some younger people looking to improve their cognition. It works by getting rid of lipofuscin/beta-amyloid pigmentation build-up in the brain. This clean up process results in slowing down and even reversing the effects of aging on the brain. Because of this ability, it is being researched for its potential as a treatment for other cognitive problems.
Maclofenoxate can be used as nootropic enhancer and can help improve memory and prevent memory loss in the elderly. It can also help to stabilize mood, increase mental focus, and heighten alterness because it increases levels of DMAE (dimethylethanolamine) in the brain. It increases DMAE levels because it is a high quality source of choline, which is vital to the brain. This nutrient is transported in the blood to the brain, but if choline levels are too low, it is removed from the brain and transported back into the bloodstream for use in other parts of the body. Meclofenoxate is a much higher quality choline source than many others, with better absorption into the blood, because it contains DMAE, which the liver can convert into choline. Once Choline reaches the brain, it can be converted into the neurotransmitter acetylcholine. This is one of the most important neurotransmitters because it is related to memory, focus, and reasoning. High levels of acetylcholine can help with improving information retention, learning, and synaptic plasticity. Acetylcholine deficiency can lead to memory loss, cognitive decline, senile dementia, and Alzheimer’s.
For elderly patients who want to use it therapeutically to reduce lipofuscin, 3-6 doses of 250mg centrophenoxine is generally recommended. For younger individuals who want a brain enhancer and neuronal protection, 1-3 doses of 250mg is often recommended.
- Farsa O. Chromatographic behaviour predicts the ability of potential nootropics to permeate the blood-brain barrier. Sci Pharm. 2013 Mar;81(1):81-91. PMID: 23641330.
- Nehru B1, Verma R, Khanna P, Sharma SK. Behavioral alterations in rotenone model of Parkinson’s disease: attenuation by co-treatment of centrophenoxine. Brain Res. 2008 Mar 27;1201:122-7. PMID: 18308296.